Cipla in talks to add new customers for its China factory, executive says

Indian pharmaceutical giant Cipla is exploring at least two new overseas markets for products made at its Chinese manufacturing plant, as it grapples with limited production capacity in India. The company began producing inhalation respule products at its Jiangsu facility in 2024 to supply the U.S., and is now in talks with other countries to expand exports.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eEWsRNJ
via IFTTT